Young startups backed by nanoparticle tech face a world hurdles before reaching the clinic. It’s been decades since the first innovations with nanotechnology – and experts are asking, “Where are all the drugs?” It’s been more than 20 years since the FDA approved the first nanoparticle drug, Doxil. At the time, nanoparticles were heralded as a […]
Catalent
Catalent soars on Q3 earnings, sales beat
Shares in Catalent (NYSE:CTLT) jumped more than 20% last week after the company beat expectations on Wall Street with its fiscal 3rd quarter results. The Somersert, N.J.-based company posted profits of $26 million, or 21¢ per share, on sales of $532.6 million for the 3 months ended March 31, for bottom-line growth of 143% on sales growth […]
Sanofi gains on Q4 results; a look at some of the top drug-delivery earners in 2016
Shares in Sanofi (NYSE:SNY) have gained 11% to $44.58 apiece since the company released its 4th-quarter and full year 2016 financial results in February. The French company posted profits of $731.5 million on sales of $8.21 billion for the 3 months ended Dec. 31, for bottom-line growth of 136.5% on sales growth of 3.3% compared with […]
Catalent acquires soft-gel manufacturer Accucaps
Catalent (NYSE:CTLT) said today that it closed its acquisition of Canada-based Accucaps and its pharmaceutical soft-gel manufacturing capabilities. The Somerset, N.J.-based company did not disclose the deal’s financial details. In November last year, Catalent said that it planned to fund the Accucaps buy with a $400 million debt offering. The company also plans to use the private placement […]
Catalent to float $400m debt offering
Catalent (NYSE:CTLT) said today that it plans to fund its acquisition of soft-gel pharmaceutical capsule manufacturer Accucaps Industries Ltd with a $400 million debt offering. The Somerset, N.J.-based company said the private placement offering of euro-dominated senior unsecured notes due in 2024 will also be used to repay some of the outstanding borrowings under its senior […]
Catalent tops Q1 estimates, profits fall 61%
Shares in Catalent (NYSE:CTLT) rose yesterday after the drug-delivery company met expectations on Wall Street with its fiscal 1st-quarter results. The Somerset, N.J.-based company posted profits of $4.6 million, or 4¢ per share, on sales of $442.2 million for the 3 months ended Sept. 30, for a bottom-line slide of -60.7% on sales growth of 4.5% compared with […]
